Phio Pharmaceuticals holds 2026 annual meeting, expands incentive plan
Shareholders approved a 1,500,000-share increase to Phio's long-term incentive plan and elected six directors at the September 28, 2026 meeting.
SEC filing
Latest
3 stories
Monday, September 28
Thursday, August 6
Phio reports Q2 2026 results, sets Q3 FDA meeting on PH-762 path
Phio said its Phase 1b skin cancer trial finished in March 2026, with final documentation still in preparation as it plans an FDA meeting in the third quarter.
SEC filing
Tuesday, July 21
Phio Pharmaceuticals adds dermatologist R. Todd Plott to board
Phio expanded its board to six members effective July 20, 2026, naming Plott a director and a member of its Governance Committee.
SEC filing